IMM2902 significantly inhibited the growth of HER2+ breast cancer by enhancing immune cell infiltration and function, particularly showing robust anti-tumor efficacy in trastuzumab-resistant tumor models. The gene discussed is ERBB2; the disease is breast carcinoma.